ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423
This study is recruiting at 14 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on only abiraterone by PCWG3 criteria prior to study entry.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-Resistant Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Zenith Epigenetics
- Last updated on ClinicalTrials.gov
- May 8, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- California Research Institute · Los Angeles, CA
- University of California, San Francisco · San Francisco, CA
- Innovative Clinical Research Institute · Whittier, CA
Colorado · 1
- Colorado Urology · Lakewood, CO
Florida · 2
- D&H Cancer Research Center, LLC · Margate, FL
- BRCR Global · Plantation, FL
Maryland · 1
- Maryland Oncology Hematology, P.A. · Columbia, MD
Michigan · 1
- University of Michigan Rogel Cancer Center · Ann Arbor, MI
North Carolina · 1
- Messino Cancer Center · Asheville, NC
Oregon · 1
- Northwest Cancer Specialists, P.C. · Portland, OR
Tennessee · 1
- Urology Associates, P.C. · Nashville, TN
Texas · 1
- Texas Oncology - Central South · Austin, TX
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Washington · 1
- Seattle Cancer Care Alliance · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.